Domvanalimab + Zimberelimab + Capecitabine + Fluorouracil + Leucovorin + Oxaliplatin + Nivolumab
Phase 3Active 0 views this week 0 watching⚡ Active
Interest: 44/100
44
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Advanced Upper Gastrointestinal Tract Adenocarcinoma
Conditions
Advanced Upper Gastrointestinal Tract Adenocarcinoma
Trial Timeline
Nov 21, 2022 → Jun 1, 2026
NCT ID
NCT05568095About Domvanalimab + Zimberelimab + Capecitabine + Fluorouracil + Leucovorin + Oxaliplatin + Nivolumab
Domvanalimab + Zimberelimab + Capecitabine + Fluorouracil + Leucovorin + Oxaliplatin + Nivolumab is a phase 3 stage product being developed by Gilead Sciences for Advanced Upper Gastrointestinal Tract Adenocarcinoma. The current trial status is active. This product is registered under clinical trial identifier NCT05568095. Target conditions include Advanced Upper Gastrointestinal Tract Adenocarcinoma.
What happened to similar drugs?
16 of 20 similar drugs in Advanced Upper Gastrointestinal Tract Adenocarcinoma were approved
Approved (16) Terminated (1) Active (4)
Hype Score Breakdown
Clinical
17
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05568095 | Phase 3 | Active |
Competing Products
20 competing products in Advanced Upper Gastrointestinal Tract Adenocarcinoma